EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study

Daisuke Tomita, Yuji Nozaki, Rika Fukuda, Yumi Morimoto, Hirotaka Yamazawa, Kaori Ishimura, Chisato Ashida, Tetsu Itami, Toshihiko Shiga, Wataru Yamamoto, Koichi Murata, Hideo Onizawa und 10 weitere

Clinical Rheumatology · 2026-11 · 45 (11) · 6583-6593

DOI: 10.1007/s10067-026-08448-6 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 29.09.2026. Verfasst von Daisuke Tomita und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai, Osaka, 590-0197, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Antirheumatic Agents, Kidney. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION/OBJECTIVES: To evaluate clinical effectiveness and treatment persistence after renal function-guided reduced-dose initiation of Janus kinase inhibitors (JAKis) in rheumatoid arthritis (RA). METHOD: We analysed 368 adults initiating a JAKi in the ANSWER registry (2013-2023), classified as preserved renal function/standard dose (PR-Std; n = 246), preserved renal function/reduced dose (PR-Red; n = 68), or impaired renal function/reduced dose (IR-Red; n = 54). Outcomes were 6-month CDAI change, remission/LDA at days 84 and 168, and 12-month retention. IPTW addressed confounding; time-dependent Cox models evaluated dosing strategy × log(time + 1) interactions. RESULTS: Weighting improved covariate balance (standardised mean differences ≤ 0.20; most ≤ 0.10). Six-month CDAI improvement was similar across groups, and no between-group contrast in ΔCDAI at days 28, 56, 84, or 168 reached statistical significance. At Day 168, IPTW-weighted low disease activity rates were 58.5% in PR-Std, 66.9% in PR-Red, and 68.2% in IR-Red, while remission rates were 21.7%, 19.9%, and 21.1%, respectively. IPTW-weighted 12-month retention was 0.53, 0.67, and 0.44, respectively. Adverse-event-related discontinuation was not clearly higher with reduced-dose initiation. CONCLUSIONS: Reduced-dose initiation showed no clear differences in 6-month CDAI outcomes or 12-month persistence versus standard-dose initiation; however, the modest reduced-dose sample sizes and wide CIs preclude excluding small but clinically meaningful differences. Because systematic safety outcomes were not captured, AE-related discontinuation should be interpreted only as a proxy for tolerability. Key Points • Renal function-guided reduced-dose initiation of JAK inhibitors showed no clear differences in 6-month CDAI outcomes compared with standard-dose initiation. • Remission and low disease activity rates at days 84 and 168 were broadly similar across dosing groups. • In patients with preserved renal function, reduced-dose initiation showed numerically higher 12-month retention, although absolute differences were modest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsAntirheumatic AgentsKidneyHumansFemaleMaleMiddle AgedTreatment OutcomeAgedRemission InductionRegistriesDose-Response Relationship, DrugAdultCohort Studies

Stichwörter der Autor:innen

Cohort studiesDose–response relationshipJanus kinase inhibitorsRenal insufficiencyRheumatoid arthritisTreatment outcome

Substanzen

Janus Kinase InhibitorsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai, Osaka, 590-0197, Japan.
  • Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai, Osaka, 590-0197, Japan. yuji0516@med.kindai.ac.jp.
  • Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Okayama, Japan.
  • Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Orthopaedic Surgery, Faculty of Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.

Zitieren

APA

Tomita, D., Nozaki, Y., Fukuda, R., Morimoto, Y., Yamazawa, H., Ishimura, K., Ashida, C., Itami, T., Shiga, T., Yamamoto, W., Murata, K., Onizawa, H., Hashimoto, M., Katsushima, M., Ebina, K., Shirasugi, I., Ueda, Y., Son, Y., Yoshida, N., …, & Kinoshita, K. (2026). Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study. Clinical Rheumatology, 45(11), 6583-6593. https://doi.org/10.1007/s10067-026-08448-6

Vancouver

Tomita D, Nozaki Y, Fukuda R, Morimoto Y, Yamazawa H, Ishimura K, et al. Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study. Clinical Rheumatology. 2026;45(11):6583-6593. doi:10.1007/s10067-026-08448-6

BibTeX
@article{Tomita2026,
  author = {Tomita, Daisuke and Nozaki, Yuji and Fukuda, Rika and Morimoto, Yumi and Yamazawa, Hirotaka and Ishimura, Kaori and Ashida, Chisato and Itami, Tetsu and Shiga, Toshihiko and Yamamoto, Wataru and Murata, Koichi and Onizawa, Hideo and Hashimoto, Motomu and Katsushima, Masao and Ebina, Kosuke and Shirasugi, Iku and Ueda, Yo and Son, Yonsu and Yoshida, Naofumi and Takeuchi, Tohru and Matsuda, Shogo and Kinoshita, Koji},
  title = {Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {11},
  pages = {6583--6593},
  doi = {10.1007/s10067-026-08448-6}
}
Kostenlos starten →